Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis

Abstract

MTD improves the 3- and 6-mo survival rates in patients with severe AH. Alcohol abstinence is a key factor for survival in these patients. The patients who received the combination therapy with MTD were more likely to maintain abstinence than those who received monotherapy with either PDN or PTX.